CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MultiCell Technologies, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MultiCell Technologies, Inc.
68 Cumberland St Ste 301
Phone: (401) 762-0045p:401 762-0045 WOONSOCKET, RI  02895-3332  United States Ticker: MCETMCET

Business Summary
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
8/31/201511/30/2014YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secr W. Gerald G.Newmin 82 12/21/2007 12/1/1995
Director StephenChang 60 12/21/2007 6/16/2004
Director Grant G.Miller 64 10/19/2012 10/19/2012
Independent Director Thomas A.Page 86 9/11/2003 9/11/2003
Independent Director EdwardSigmond 61 5/17/2000 5/17/2000

Business Names
Business Name
MCET
MCT Rhode Island Corp.
MultiCell Immunotherapeutics, Inc.
MultiCell Technologies, Inc.
Xenogenics Corporation

General Information
Number of Employees: 2 (As of 11/30/2012)
Outstanding Shares: 5,000,948,700 (As of 10/8/2015)
Shareholders: 597
Stock Exchange: OTC
Federal Tax Id: 521412493
Fax Number: (401) 762-0098


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, February 24, 2021